In this episode, Dennis Walker and Ash Ritter dive into the world of the infamous Amanita Muscaria mushroom, as well as learn about the wild desert apothecary of fungi and herbs that she researches and teaches about.
Similar Posts
MindMed Expands MICRODOSING trials (BIG MMED/MMEDF stock UPDATE)
In today’s episode “MindMed Expands Microdosing Trials”, we’ll discuss a Big MindMed Stock Update.
On January 12th, MindMed ticker symbol (NEO: MMED ) and (OTC:MMEDF) put out a Press Release entitled MindMed Expands Psychedelic Microdosing Division, Adds Groundbreaking Study Evaluating LSD Microdosing Through Next-Gen Digital Clinical Markers. In other words, MindMed is expanding its LSD microdosing studies from just looking at how they can help those with adult ADHD, to how they could affect a more general population. This is BIG news the MindMed team and us shareholders.
As I mentioned in one of our previous episodes : “Why I’m More Excited About MindMed’s 18-MC than its LSD treatments”, MindMed has a diverse pipeline with other experiential drugs such as LSD for anxiety and psilocybin to treat ADHD. And If these trials come back successful, it’ll be the beginning of more LSD microdosing studies for MindMed.
In this episode, we will do three things:
1:We’ll read the Press Release and discuss what it means, in layman’s terms
2: We’ll enter the Speculation Zone to discuss the potential effects of this move
3: We’ll discuss how this expansion affects MindMed stock as an investment
So, what does this all mean for investors?
Can we assume that MindMed’s LSD microdosing to treat ADHD trial is going well? This, even without the new trials, would be very good news for us long term investors. Moreover, this new study shows that MindMed is continuing to expand their potential product pipeline which will also look great for the MMED/ MMEDF Stock.
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://mindmed.co/news/press-release/mindmed-expands-psychedelic-microdosing-division-adds-groundbreaking-study-evaluating-lsd-microdosing-through-next-gen-digital-clinical-markers/
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MMED #MMEDF
Interview With Stephen Murphy
Stephen Murphy, Co-Founder of Prohibition Partners, chats about the upcoming PSYCH Investor Summit taking place on April 21, 2021.
Rose Hill: Perfecting the Art of Psilocybin Cultivation with Charles Lazarus, Kevin Bourke and Domenic Suppa
In this episode, we delve into the fascinating realm of psilocybin cultivation, innovation, and exploration with the co-founding managing partners of Rose Hill, a pioneering company based in Jamaica.
Interview With Dr. Hyder A. Khoja
In this episode, Global Trac Solution’s CEO, David Flores, sits down with Dr. Hyder A. Khoja to learn more about the work they’re doing at Transcendent Therapeutics Inc.
Wesana Health’s Dr. ABID NAZEER – The Parallels Between Brain Injury & Addiction (WESA)
Wesana Health’s Dr. ABID NAZEER – The Parallels Between Brain…
The Spotlight Round Up Video, March 31st
As we continue to strive to be the leading source for news and unique perspective within the emerging sector of medicinal psychedelics, we are excited to debut the Spotlight Roundup! This video series, produced in collaboration with Elk’s Pride Pictures, provides a concise and informative roundup related to some of the most important news developments happening within this rapidly expanding industry. From the latest IPO’s, to new clinical trials, the Spotlight Roundup covers everything you need to know!